On this page
VHL
von Hippel-Lindau tumor suppressor
The VHL gene encodes a tumour suppressor protein that regulates cellular responses to oxygen levels and controls the degradation of proteins involved in blood vessel formation. VHL produces a protein component of the VCB-CUL2 complex, which marks other proteins for breakdown when they are no longer required.
VHL is located on the short (p) arm of chromosome 3, at band 3p25.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The VHL gene, located on chromosome 3, provides instructions for making the von Hippel-Lindau tumour suppressor protein. This 213-amino-acid protein functions within a larger molecular assembly that identifies and tags unwanted proteins for destruction by the cell's recycling machinery. Through this role, VHL maintains appropriate protein levels in response to changing oxygen availability, preventing the inappropriate accumulation of factors that drive blood vessel formation and cell growth.
Pathogenic variants in VHL follow an autosomal dominant inheritance pattern, meaning a single altered copy can predispose individuals to tumour development. The gene has been extensively studied because inherited changes underlie von Hippel-Lindau syndrome, a condition in which benign and malignant tumours arise in the brain, spinal cord, retina, kidneys, adrenal glands, and pancreas. Non-inherited changes in VHL are also found in sporadic clear cell renal carcinoma, the most common form of kidney cancer. The VHL protein's function as a gatekeeper for cell division and blood vessel growth explains why its loss or dysfunction leads to uncontrolled tissue proliferation.
Because of the serious and actionable nature of VHL-related conditions, this gene is included on the American College of Medical Genetics and Genomics list of secondary findings that clinical laboratories may report when identified incidentally during genomic sequencing. In the UK, VHL appears on multiple NHS Genomic Medicine Service panels covering inherited cancers, endocrine tumours, and kidney disease. Early identification of pathogenic VHL variants enables proactive surveillance programmes that can detect tumours at earlier, more treatable stages.
What the gene does
The VHL protein operates as the substrate recognition component of a multi-protein assembly known as the VCB-CUL2 complex, which also includes elongin B, elongin C, cullin-2, and a RING-box protein. This complex functions as an E3 ubiquitin ligase, attaching ubiquitin molecules to target proteins and thereby marking them for degradation by the proteasome. The specificity of this system relies on VHL's ability to recognise particular target proteins when they have been post-translationally modified, particularly through hydroxylation of proline residues.
One of the most critical targets of the VCB-CUL2 complex is hypoxia-inducible factor 2-alpha (HIF-2α), a transcription factor subunit that activates genes in response to low oxygen conditions. Under normal oxygen levels, enzymes called prolyl hydroxylases add hydroxyl groups to specific proline residues on HIF-2α, creating a binding site for VHL. Once VHL recognises and binds hydroxylated HIF-2α, the entire VCB-CUL2 machinery ubiquitinates the transcription factor, leading to its rapid destruction. This mechanism ensures that HIF-2α and its partner HIF-1α remain active only when oxygen is genuinely scarce. When VHL function is lost, HIF proteins accumulate even in oxygen-rich environments, inappropriately activating genes that promote red blood cell production, glucose metabolism, and the formation of new blood vessels through angiogenesis.
The VHL protein contains distinct functional regions that enable its dual roles in substrate recognition and complex assembly. The region spanning amino acids 157 to 166 mediates interaction with the elongin B and elongin C subunits, anchoring VHL within the larger E3 ligase complex. A separate portion of the protein, from residues 100 to 155, appears to be involved in binding to the CCT chaperonin complex, which may assist in proper folding of the VHL protein itself. The N-terminal region, encompassing amino acids 1 to 65, is largely disordered and contains eight tandem repeats of a five-amino-acid motif. While the precise function of these repeats remains under investigation, they may contribute to protein-protein interactions or regulatory modifications.
Beyond its role in HIF regulation, VHL influences additional cellular processes including microtubule stability, extracellular matrix assembly, and the control of genes involved in cell cycle progression. Research suggests that VHL participates in maintaining the structure of primary cilia, antenna-like projections on cell surfaces that sense environmental signals. The protein's broad involvement in cellular architecture and signalling pathways underscores why its loss has such profound effects on tissue organisation and growth control. As a bona fide tumour suppressor, VHL prevents the unchecked cell division characteristic of cancer when both gene copies are functional.
Video: Genetics 101
Chromosome location
The VHL gene resides on the short arm of chromosome 3 at cytogenetic band 3p25.3, a region near the chromosome's telomeric end. This genomic location spans approximately 10 kilobases and contains three exons that are transcribed and spliced to produce the mature messenger RNA template for VHL protein synthesis. The gene's position in the 3p25 region is clinically significant because deletions encompassing this chromosomal segment can remove VHL along with neighbouring genes, occasionally resulting in contiguous gene syndromes with features beyond those of isolated VHL deficiency.
The relatively small size of the VHL gene, combined with its compact exonic structure, facilitates comprehensive genetic testing through both sequencing and deletion/duplication analysis. Loss of heterozygosity at the 3p25 locus is a hallmark of clear cell renal carcinoma, where inactivation of both VHL gene copies through a combination of inherited or acquired mutation and chromosomal loss drives tumour initiation. The chromosomal band 3p25.3 falls within a broader region of 3p that harbours multiple tumour suppressor genes, and larger deletions in this area can contribute to more severe or complex clinical presentations.
Protein structure
The VHL protein comprises 213 amino acids organised into functionally distinct regions that enable its role within the VCB-CUL2 ubiquitin ligase complex. The N-terminal portion, spanning amino acids 1 to 65, is classified as a disordered region lacking stable three-dimensional structure. Within this disordered segment lie eight tandem repeats of a five-amino-acid motif (residues 14 to 53), each conforming to the pattern glycine-[proline/alanine/valine/glycine]-glutamate-glutamate-[aspartate/alanine/tyrosine/serine/leucine/glutamate]. These repeats, individually designated as Repeat 1 through Repeat 8 and occupying residues 14-18, 19-23, 24-28, 29-33, 34-38, 39-43, 44-48, and 49-53 respectively, may serve regulatory or interaction functions despite their lack of fixed structure.
The central and C-terminal portions of VHL adopt more defined conformations essential for complex assembly and substrate recognition. The region involved in binding to the CCT chaperonin complex extends from amino acids 100 to 155, suggesting that proper folding of VHL depends on assistance from molecular chaperones. Further towards the C-terminus, the segment from residues 157 to 166 mediates interaction with the elongin B and elongin C subunits, forming the stable core of the VCB-CUL2 assembly. This interaction region is critical because it anchors VHL within the functional E3 ligase and positions the protein to present substrates for ubiquitination.
Structural studies have revealed that VHL forms two distinct domains: a beta-domain responsible for substrate binding and an alpha-domain that contacts elongin C. The interface between these domains creates the binding pocket that recognises hydroxylated proline residues on target proteins such as HIF-2α. Pathogenic variants are distributed throughout the protein sequence, with missense changes frequently disrupting either the substrate-binding interface or the surfaces required for elongin interaction. Truncating variants that prematurely terminate translation typically result in complete loss of function because they eliminate essential C-terminal structural elements.
Key variants
More than 370 distinct inherited pathogenic variants in the VHL gene have been documented in families affected by von Hippel-Lindau syndrome, with additional somatic changes identified in sporadic tumours. These variants span the full spectrum of genetic alterations, including missense substitutions that produce an altered protein, nonsense changes that introduce premature stop codons, small insertions or deletions causing frameshifts, and larger deletions removing one or more exons. The functional consequence of these variants is typically either absent VHL protein production or synthesis of a protein unable to perform its substrate-recognition and degradation functions.
Genotype-phenotype correlations have emerged from studying large cohorts of affected families. Variants that completely abolish VHL protein expression or severely disrupt the elongin-binding region tend to associate with a high risk of clear cell renal carcinoma, whilst certain missense changes that partially preserve protein function correlate with lower kidney cancer risk but elevated rates of phaeochromocytoma. A subset of variants causes isolated familial erythrocytosis (ECYT2) without the broader tumour predisposition seen in classic von Hippel-Lindau syndrome; these changes specifically impair HIF-2α recognition whilst sparing other VHL functions. At least ten such variants have been characterised in families with this condition.
Variants are classified as pathogenic, likely pathogenic, of uncertain significance, likely benign, or benign according to standardised criteria that consider functional studies, segregation data, allele frequencies, and computational predictions. Because VHL is a well-established disease gene with decades of clinical and laboratory research, the majority of disease-causing variants have been conclusively classified. Individuals found to carry pathogenic or likely pathogenic VHL variants are typically referred to clinical genetics services for counselling, cascade testing of at-risk relatives, and enrolment in tumour surveillance protocols tailored to their specific variant.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.191G>C | p.Arg64Pro | Pathogenic | ★★★☆ | Pheochromocytoma |
c.194C>G | p.Ser65Trp | Pathogenic | ★★★☆ | Von Hippel-Lindau syndrome |
c.208G>T | p.Glu70Ter | Pathogenic | ★★★☆ | Von Hippel-Lindau syndrome |
c.233A>G | p.Asn78Ser | Pathogenic | ★★★☆ | Von Hippel-Lindau syndrome |
c.257C>T | p.Pro86Leu | Pathogenic | ★★★☆ | Von Hippel-Lindau syndrome |
c.263G>A | p.Trp88Ter | Pathogenic | ★★★☆ | not provided |
c.341-2A>G | - | Pathogenic | ★★★☆ | Von Hippel-Lindau syndrome |
c.408del | p.Phe136fs | Pathogenic | ★★★☆ | Von Hippel-Lindau syndrome |
c.422dup | p.Asn141fs | Pathogenic | ★★★☆ | Von Hippel-Lindau syndrome |
c.463+1G>A | - | Pathogenic | ★★★☆ | Chuvash polycythemia |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in VHL are associated with two primary inherited conditions that differ in their clinical features and underlying molecular mechanisms. Von Hippel-Lindau syndrome, the more extensively recognised of the two, presents with multiple tumour types affecting the central nervous system, eyes, kidneys, adrenal glands, and pancreas. These growths include haemangioblastomas (benign but potentially symptomatic vascular tumours of the brain and spinal cord), retinal angiomas, renal cysts and clear cell carcinomas, phaeochromocytomas (catecholamine-secreting adrenal tumours), and pancreatic neuroendocrine tumours and cysts. The syndrome follows an autosomal dominant pattern, meaning that offspring of an affected individual have a 50 per cent chance of inheriting the pathogenic variant.
Primary familial erythrocytosis type 2 (ECYT2), also inherited in an autosomal dominant manner, presents quite differently as an isolated increase in red blood cell mass without the tumour predisposition of classic von Hippel-Lindau syndrome. Individuals with ECYT2 have elevated haemoglobin and haematocrit levels, which can increase the risk of abnormal blood clots but do not involve the multi-organ tumour development seen with other VHL variants. This phenotypic distinction arises because ECYT2-associated variants selectively disrupt VHL's ability to regulate HIF-2α, leading to constitutive activation of erythropoietin production, whilst preserving other tumour-suppressor functions of the protein.
Beyond these inherited conditions, non-inherited (somatic) changes in VHL play a central role in sporadic clear cell renal carcinoma, the most prevalent form of kidney cancer. These acquired mutations occur only in kidney tissue and are not passed to offspring. Some individuals with von Hippel-Lindau syndrome develop phaeochromocytomas or paragangliomas without the full constellation of syndrome features, a presentation sometimes termed nonsyndromic paraganglioma. Haemangioblastomas of the brain and spine can also occur sporadically in the absence of other VHL syndrome manifestations.
Inheritance pattern
Conditions caused by pathogenic VHL variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
The VHL gene holds green (high confidence) status across 19 specialist panels within the NHS Genomic Medicine Service, reflecting robust evidence for its role in clinically actionable conditions. It appears on both adult-focused panels, such as Adult Solid Tumours Cancer Susceptibility and Inherited Renal Cancer (R224), and paediatric panels including Childhood Solid Tumours Cancer Susceptibility. The gene's inclusion spans multiple organ systems: it features on Endocrine Neoplasia (R217), Inherited Phaeochromocytoma and Paraganglioma (R223), Cystic Kidney Disease, and Familial Tumours Syndromes of the Central and Peripheral Nervous System.
VHL is also listed on three Additional Findings Health Related panels (standard, paediatric, and CNV analysis for children), which guide the return of medically actionable incidental findings from genomic testing. Its presence on the dedicated Von Hippel-Lindau Syndrome panel (R225) ensures that individuals with suggestive clinical features receive appropriate genetic testing and that pathogenic variants are interpreted within established diagnostic guidelines. The Hereditary Erythrocytosis panel (R405) captures VHL's role in primary familial erythrocytosis type 2, whilst the Unexplained Kidney Failure in Young People and Multiple Endocrine Tumours panels reflect the gene's broad relevance to renal and endocrine pathology. This extensive panel coverage ensures that VHL variants are considered in diverse clinical scenarios, facilitating early diagnosis and proactive management for carriers.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with a pathogenic VHL variant, regular clinical surveillance is the cornerstone of medical management, and lifestyle modifications play a supportive rather than preventive role. General population research suggests that maintaining a healthy body weight and engaging in regular physical activity may contribute to overall cancer risk reduction, though no specific dietary or exercise intervention has been proven to prevent tumour development in VHL variant carriers. Some observational studies in the broader population indicate that diets rich in fruits, vegetables, and whole grains, whilst limiting processed meats and excessive alcohol, are associated with modestly lower cancer incidence, but these associations have not been specifically validated in the context of inherited VHL-related tumours.
Smoking cessation is strongly encouraged for all individuals, and this recommendation is particularly relevant for those with inherited cancer predisposition syndromes. Research in general populations suggests smoking may influence cancer outcomes, and avoiding tobacco may therefore offer some benefit to VHL variant carriers, though direct evidence from prospective trials in this specific group is lacking. Adequate hydration and avoidance of nephrotoxic substances (certain medications, excessive non-steroidal anti-inflammatory drug use) are sensible precautions for kidney health, given the risk of renal cysts and carcinoma in von Hippel-Lindau syndrome.
Physical trauma to the head should be minimised where practical, as individuals with VHL syndrome can develop cerebellar and spinal haemangioblastomas that may be vulnerable to haemorrhage or neurological compromise if subjected to significant impact. However, this does not mean affected individuals must avoid all physical activity; rather, high-contact sports might be approached with greater caution, and decisions about participation should involve discussion with a specialist familiar with the individual's tumour burden. Any lifestyle modifications should be considered alongside, not in place of, the structured surveillance protocols (typically involving regular brain and spinal imaging, abdominal scans, and ophthalmological examinations) that form the evidence-based standard of care for VHL variant carriers.
Supplement considerations
There is currently no conclusive scientific evidence that any dietary supplement can prevent tumour development or alter disease progression in individuals carrying pathogenic VHL variants. Whilst antioxidant supplements such as vitamin C, vitamin E, and selenium are sometimes promoted for general cancer prevention, there is insufficient evidence that supplements prevent VHL-related tumours. The unique biology of VHL-related tumours, which involve dysregulated oxygen sensing and angiogenesis rather than simple oxidative damage, makes it unlikely that antioxidant supplementation would address the underlying molecular defect.
Some experimental research has explored whether compounds that modulate hypoxia-inducible factor pathways might have therapeutic potential in VHL-deficient contexts, but these investigations remain at early stages and have not translated into evidence-based supplement recommendations. Individuals with VHL syndrome should be particularly cautious about supplements marketed to boost red blood cell production or enhance vascularity, as these could theoretically exacerbate the pathological processes driven by loss of VHL function. Any consideration of supplement use should involve consultation with a healthcare provider familiar with the individual's specific clinical situation, especially given that some supplements can interact with surveillance imaging or interfere with medications used to manage complications such as hypertension associated with phaeochromocytoma.
Maintaining adequate but not excessive intake of nutrients through a balanced diet is a reasonable approach, and individuals should discuss with their clinical team whether routine monitoring of vitamin D, iron, or other micronutrients is appropriate based on their overall health status. However, it is important to emphasise that no supplement regimen can substitute for the regular imaging surveillance and prompt clinical intervention that form the established standard of care for VHL variant carriers.
Frequently asked questions
What is the difference between von Hippel-Lindau syndrome and primary familial erythrocytosis type 2?
Both conditions result from inherited VHL variants, but they differ markedly in presentation. Von Hippel-Lindau syndrome involves multiple tumour types affecting the brain, eyes, kidneys, and adrenal glands, whilst primary familial erythrocytosis type 2 causes only an elevated red blood cell count without tumour predisposition. The distinction arises because ECYT2-associated variants selectively impair regulation of erythropoietin production whilst preserving VHL's broader tumour-suppressor functions.
How often should someone with a pathogenic VHL variant undergo surveillance imaging?
Surveillance protocols are individualised based on age, variant type, and personal or family history, but typically include annual or biennial brain and spinal MRI, abdominal CT or MRI, and ophthalmological examination beginning in childhood or adolescence. A clinical genetics service or specialist familiar with VHL syndrome should coordinate the specific surveillance schedule, as recommendations may evolve with emerging evidence and individual risk factors.
Can children inherit a VHL variant even if their parent shows no symptoms?
Yes, because von Hippel-Lindau syndrome exhibits age-related penetrance, meaning some carriers develop symptoms later in life or have milder manifestations that escape detection. If a parent carries a pathogenic VHL variant, each child has a 50 per cent chance of inheriting it regardless of whether the parent has experienced clinical features. Cascade testing of at-risk relatives is recommended once a pathogenic variant is identified in the family.
Does having a VHL variant mean kidney cancer is inevitable?
Not every individual with a pathogenic VHL variant will develop renal cell carcinoma, as penetrance varies by specific variant and other genetic or environmental factors. However, the lifetime risk is substantially elevated compared to the general population, which is why regular renal imaging surveillance is recommended. Early detection through surveillance enables intervention before tumours become large or metastatic, significantly improving outcomes.
Are there targeted treatments for tumours caused by VHL variants?
Management strategies depend on tumour location, size, and symptoms, and may include surgical resection, laser treatment for retinal lesions, or active monitoring for small, asymptomatic growths. For metastatic clear cell renal carcinoma associated with VHL loss, therapies targeting vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathways have shown clinical benefit, as these pathways are aberrantly activated when VHL function is lost. Treatment decisions should be made in consultation with specialists experienced in managing VHL-related disease.
Should someone with a VHL variant avoid high altitudes?
There is no strong evidence that altitude exposure directly worsens VHL-related tumours, though high altitude naturally reduces oxygen availability and activates hypoxia-inducible factors. Most individuals with VHL syndrome can travel and reside at altitude without specific restrictions, but those with significant tumour burden, particularly haemangioblastomas or phaeochromocytomas, should discuss travel plans with their clinical team to ensure appropriate precautions and access to medical care if needed.
References
- Burnichon N, Vescovo L, Amar L. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human molecular genetics. 2011. PMID: 21784903
- McMullin MF. HIF pathway mutations and erythrocytosis. Expert review of hematology. 2010. PMID: 21082936
- Percy MJ, Rumi E. Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. American journal of hematology. 2009. PMID: 19006225
- Percy MJ. Genetically heterogeneous origins of idiopathic erythrocytosis. Hematology (Amsterdam, Netherlands). 2007. PMID: 17454194
- Kaelin WG Jr. The von hippel-lindau tumor suppressor protein: an update. Methods in enzymology. 2007. PMID: 17998064
- Kaelin WG. Von Hippel-Lindau disease. Annual review of pathology. 2007. PMID: 18039096
- Maranchie JK, Afonso A, Albert PS. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Human mutation. 2004. PMID: 14695531
- Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. American journal of physiology. Renal physiology. 2004. PMID: 15180922
- Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15611513
- Pastore Y, Jedlickova K, Guan Y. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. American journal of human genetics. 2003. PMID: 12844285
- Neumann HP, Bausch B, McWhinney SR. Germ-line mutations in nonsyndromic pheochromocytoma. The New England journal of medicine. 2002. PMID: 12000816